Awakn Life Sciences’ Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66%… Jul 20, 2022
Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs Jul 19, 2022
Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead… Jul 5, 2022
Awakn Life Sciences Appoints Biotech and Investment Veteran Dennis Purcell as a Special Advisor to the CEO Jun 7, 2022
Awakn Life Sciences CEO, Anthony Tennyson, Joins Dustin Robinson of Iter Investments for ‘The Investor… May 24, 2022
